As we emerge from another surge in coronavirus cases, there is good reason to believe we are starting 2022 in a better position than we were this time last year.  Yet uncertainty remains. COVID-19 will have a lasting effect on healthcare budgets, as well as in areas such as clinical trials, regulatory processes and reimbursement timelines. At the same time, we are at the cusp of another wave of innovation, with a raft of new treatment modalities due to launch in the coming 12 months.

What can we expect in terms of policy developments, and how will payers manage already-constrained drugs budgets in in the wake of the pandemic? To hear the answers to these questions, join us for a lively discussion with our panel of payer experts from around the world.